Notable
Nicotinamide With Oral Tetrahydrouridine and Decitabine · High Risk Sickle Cell Disease
Primary completion pushed from Oct 30, 2026 to Oct 30, 2028
Also in this update: Study completion pushed from Apr 30, 2027 to Jan 20, 2029
EpiDestiny, Inc.Phase 1 NCT04055818 Registry history of NCT04055818 on ClinicalTrials.gov (opens the registry)